"Having served on the search committee, I had the opportunity to evaluate a number of strong candidates. Ms. Devlin stood out as our top choice," said Dr. Albert Roeder, COO and a member of the company's Board of Directors. "Her skill set richly complements our current capabilities and strengthens our future commercialization plans."
"It is an honor to join Genelux Corporation as the company's first President," said Ms. Devlin. "I am excited to help bring such innovative and potentially life-saving technology to cancer patients and to rapidly advance the company's tremendous portfolio of therapeutics and diagnostics. I look forward to working with Dr. Szalay, the Board of Directors, and our management team for the benefit of cancer patients while generating value for our shareholders. In addition, I will continue to build upon the positive and rewarding environment for our employees."
About Genelux Corporation
Genelux Corporation was founded in 2001 with a mission to develop safe and effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there are no effective treatments today. Genelux Corporation is headquartered in San Diego, California,
Genelux Forward Looking Statement
Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks assoc
|SOURCE Genelux Corporation|
Copyright©2010 PR Newswire.
All rights reserved